Effects of risperidone combined with metformin on homocysteine levels and glycolipid metabolism in patients with schizophrenia
10.3760/cma.j.cn341190-20240313-00253
- VernacularTitle:利培酮联合二甲双胍对精神分裂症患者同型半胱氨酸、糖脂代谢的影响
- Author:
Yanshuang LI
1
;
Guomin WANG
1
Author Information
1. 衢州市第三医院精神康复科，衢州 324003
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Drug therapy,combination;
Metformin;
Cysteine;
Blood glucose;
Insulin;
Cholesterol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(5):641-645
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of risperidone combined with metformin on homocysteine levels and glycolipid metabolism in patients with schizophrenia.Methods:A randomized controlled study was conducted involving 124 patients with schizophrenia who received treatment at Quzhou Third Hospital from January 2022 to June 2023. The patients were divided into a study group and a control group, with 62 patients in each group, based on a random number table. The study group was treated with risperidone combined with metformin, while the control group received risperidone treatment along with a placebo of the same dose as metformin. The treatment duration for both groups was 3 months. Clinical efficacy was evaluated, and changes in homocysteine levels and glycolipid metabolism were measured before and after treatment.Results:The difference in overall efficacy between the two groups was not statistically significant ( P = 0.697). After treatment, the homocysteine levels in the study group [(15.26 ± 2.11) μmol/L] were significantly lower than those in the control group [(19.01 ± 2.04) μmol/L, t = 9.87, P < 0.001]. The fasting blood glucose [(6.15 ± 0.57) mmol/L], 2-hour postprandial blood glucose [(12.41 ± 2.67) mmol/L], fasting insulin [(24.23 ± 3.21) μIU/mL], and total cholesterol [(6.04 ± 1.39) mmol/L] in the study group were all higher than those in the control group [(4.93 ± 0.45) mmol/L, (10.68 ± 2.46) mmol/L, (22.93 ± 3.05) μIU/mL, (0.91 ± 0.12) mmol/L, t = -13.23, -3.75, -2.31, -6.24, all P < 0.05]. The waist-to-hip ratio in the study group was (0.81 ± 0.09), which was significantly lower than that in the control group [(0.91 ± 0.12), t = 5.25, P < 0.001]. There was no significant difference in incidence of adverse reactions between the two groups ( P = 0.081). Conclusions:The combination of risperidone and metformin in the treatment of schizophrenia is beneficial for decreasing patients' homocysteine levels, preventing abnormalities in glycolipid metabolism, and reducing waist-to-hip ratios. This treatment demonstrates good efficacy and safety.
